Nagourney Cancer Institute is willing to test my tissue for drug senstivity but they need at least one cubic...

This is an excellent, practical question—and it shows you're thinking strategically about getting actionable information. Let me give you the straight answer about tissue volume and what Nagourney can actually do with your nodule.

The Short Answer: Yes, Your Nodule Should Be Sufficient

Your 3.2 × 3.0 cm lung nodule is likely large enough to provide the tissue Nagourney needs. Here's the math and reality:

Volume Calculation:

• A 3.2 × 3.0 cm nodule, assuming roughly spherical shape, is approximately 15-20 cubic millimeters of actual nodule tissue
• 1 cubic centimeter = 1,000 cubic millimeters
• So your nodule is roughly 1.5-2% of the volume needed

BUT—and this is important—the actual usable tissue is much less:

• A CT-guided needle biopsy typically retrieves 2-5 small tissue cores (each about 1-2mm in diameter)
• This yields roughly 50-200 cubic millimeters of actual tissue (not the whole nodule)
• That's 0.05-0.2 cubic centimeters—well below the 1 cubic centimeter Nagourney requires

This is the real issue you're facing.

Why Nagourney Needs That Much Tissue

Nagourney Cancer Institute performs ex vivo chemosensitivity testing—they grow your actual tumor cells in the lab and test them against multiple drugs to see which ones kill your cancer most effectively. This is different from standard biomarker testing.

Why they need substantial tissue:

• They need enough viable tumor cells to culture (grow) in multiple wells
• Testing multiple drug combinations requires multiple samples
• Not all tissue retrieved is viable (some is necrotic/dead)
• They need margin for quality control and repeat testing if needed

This is legitimate science, but it's resource-intensive.

Your Real Options for Getting Enough Tissue

Option 1: Larger Biopsy Procedure

CT-Guided Core Needle Biopsy with Multiple Passes:

• Instead of standard 2-3 passes, radiologist does 5-8 passes specifically to maximize tissue yield
• Can retrieve 300-500+ cubic millimeters of tissue
• Increases pneumothorax risk slightly (maybe 25-35% vs. standard 15-20%)
• Takes longer (45-60 minutes vs. 30-45 minutes)
• This is probably your best option if you want to pursue Nagourney testing

Tell your radiologist upfront: "I need maximum tissue yield for ex vivo drug sensitivity testing—can you do multiple passes?"

Option 2: Surgical Biopsy (VATS)

Video-Assisted Thoracic Surgery:

• Minimally invasive surgery with 2-3 small incisions
• Can remove entire nodule or large wedge of tissue
• Guarantees >1 cubic centimeter of tissue
• More invasive: requires anesthesia, 1-2 day hospital stay, 1-2 week recovery
• Higher risk than needle biopsy but very manageable
• Better for you if: needle biopsy fails, or you want maximum tissue AND can tolerate surgery

Option 3: Combination Approach

• Needle biopsy first (lower risk, faster)
• If tissue is insufficient, proceed to VATS
• Gives you a chance to assess tolerance before committing to surgery

Important Context: Your Current Health Status

Before pursuing aggressive tissue collection, your oncologist needs to assess:

Your Bleeding Risk:

• Your hematocrit is 32.7% (mild anemia)—this increases bleeding risk slightly
• Your platelet count wasn't listed—this is critical. If platelets are <100, biopsy risk increases significantly
• Ask your oncologist: "What's my platelet count? Should we transfuse before biopsy?"

Your Liver Status:

• Your AST is elevated at 57 U/L (normal ~30-40)
• This reflects liver stress from cancer spread and your recent hepatic abscesses
• Liver dysfunction can affect clotting factors, increasing bleeding risk
• This is manageable but needs to be factored in

Your Performance Status:

• Can you tolerate a more aggressive biopsy procedure?
• Can you tolerate potential complications (pneumothorax, bleeding)?
• If VATS is needed, can you handle surgery and recovery?

The Nagourney Question: Is It Worth It?

This is where I need to be honest with you about the evidence:

What Nagourney Does:

• Ex vivo drug sensitivity testing is scientifically sound—they grow your tumor cells and test drugs
• Results can be informative about which drugs your cancer responds to

The Evidence Reality:

• No randomized controlled trials show that Nagourney testing improves survival or outcomes in pancreatic cancer
• ASCO (American Society of Clinical Oncology) does not recommend routine use of ex vivo drug sensitivity testing outside of clinical trials
• NCCN Guidelines do not include Nagourney testing as a standard recommendation for pancreatic cancer

What this means:

• The testing is real and the science is legitimate
• But it's not standard of care and outcomes data in pancreatic cancer specifically are limited
• Your insurance may not cover it (it's often $3,000-5,000+)
• Results might be interesting but may not change your oncologist's recommendations

What WOULD Be Standard: Tissue Biomarker Testing

Instead of (or in addition to) Nagourney, standard biomarker testing from your lung nodule would include:

• BRCA1/BRCA2 mutations → opens platinum + PARP inhibitor options
• KRAS mutations (specific variants) → newer targeted therapies (sotorasib, adagrasib)
• MSI/dMMR status → immunotherapy eligibility (you're pMMR now, but metastatic site might differ)
• PD-L1 expression → immunotherapy combinations
• PALB2, TP53, SMAD4 → prognostic and therapeutic information

This testing requires far less tissue (standard needle biopsy is usually sufficient) and has clear clinical implications.

My Recommendation: Questions for Your Oncologist

1. "Before pursuing Nagourney testing, should we do standard biomarker testing (BRCA, KRAS variants, MSI, PD-L1) from the lung nodule? How would each result change my treatment?"

2. "If we do pursue Nagourney testing, what's my platelet count? Would I need transfusion before biopsy?"

3. "For maximum tissue yield, would you recommend multiple-pass needle biopsy or VATS? What are the risks/benefits for me specifically?"

4. "If Nagourney testing shows drug sensitivity to a specific agent, would that be something you'd recommend, or would you prefer to follow standard NCCN guidelines?"

5. "What's the cost of Nagourney testing, and would my insurance cover it?"

6. "Given my progression on current therapy, what's the timeline for getting results and starting a new treatment?"

The Bottom Line

Yes, your 3.2 × 3.0 cm nodule is large enough—but only if you do an aggressive biopsy procedure (multiple passes or VATS) rather than standard needle biopsy.

However, before committing to that, I'd strongly recommend:

• Getting standard biomarker testing first (requires less tissue, has clear clinical implications)
• Discussing with your oncologist whether Nagourney testing specifically would change your treatment decisions
• Understanding that while Nagourney is scientifically interesting, it's not standard of care and outcomes data in pancreatic cancer are limited

The goal is actionable information that will actually guide your next treatment—not just interesting data.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions. Your oncologist and interventional radiologist will determine the safest biopsy approach for your specific situation and which biomarker testing is most likely to guide your next treatment decisions.